Healthcare

Clinuvel Pharmaceuticals Limited (ASX:CUV)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 28.770.67 (2.384%)

(as on 2021-12-02 11:51:13 AEDT)

Market Cap : AUD 1.424 B

Dividend Yield (Annualized) : 0.090%

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
28.1 29.5 28.77 28.610L 30.780 H 19.630L 44.670 H
Last Trade 28.77
Change% 2.3843
52 W H/L 44.670/19.630
EBITDA 28.193 M
NPAT After Abnormal Items 24.728 M
Equity 98.737 M
ROE% 25.04%
Total Liabilities 9.83 M
Total Revenue 48.108 M
Cash and Cash Equivalents 82.691 M

Stock Information

Share price 28.77
Market Cap 1.424 B
Price/Gross Cash Flow 76.79
Dividend Yield Excluding Special 0.08%
Ending Shares 49.41 M
52-Week Range 44.670-19.630
P/E ratio 59.524
Sector P/E --
EPS 48.40
EV/EBITDA 51.54
Net Profit Margin (%) 51.54%
Gross Cash Flows Per Share 0.39
Net Gearing -82.43%
Gross DPS (AUD) 0.025
Gross Dividend Yield (Annualized) 0.08%
Earnings Yield 1.680
Net Tangible Asset (NTA) 1.99
Sales Per Share 0.94
Book Value Per Share 2.00

Announcements

Heading Date/Time
Results of Meeting  11/11/2021 9:13AM
Managing Director AGM Presentation  10/11/2021 6:01PM
Chair Address  10/11/2021 5:55PM
CLINUVEL Strategic Update III - November 2021  08/11/2021 2:02PM
Media release - CLINUVEL Expands Pharmaceutical Portfolio  08/11/2021 10:02AM
CLINUVEL adds ACTH to portfolio  08/11/2021 9:56AM
Response to ASX Price Query  08/11/2021 9:05AM
Quarterly Activities/Appendix 4C Cash Flow Report  28/10/2021 9:28AM
CLINUVEL Investor Webinar Released  26/10/2021 9:31AM
First Patient Treated in CLINUVEL DNA Repair Study  22/10/2021 8:58AM
Investor Webinar  18/10/2021 8:55AM
Appendix 4G and Corporate Governance Statement  08/10/2021 11:35AM
Notice of Annual General Meeting/Proxy Form  08/10/2021 11:34AM
Annual Report to shareholders  08/10/2021 11:31AM
Operations Update Webcast II  07/10/2021 10:51AM
CLINUVEL Progresses DNA Repair Program  05/10/2021 9:45AM
CLINUVEL Key Events and Announcements  23/09/2021 9:39AM
CLINUVEL Confirms AGM Date  22/09/2021 9:33AM
Notification regarding unquoted securities - CUV  16/09/2021 12:30PM
Presentation H.C. Wainwright Global Investment Conference  14/09/2021 9:27AM
CLINUVEL Investor Webinar Financial Results  27/08/2021 10:38AM
Dividend/Distribution - CUV  26/08/2021 11:02AM
CLINUVEL Newsletter 4 - August 2021  26/08/2021 10:55AM
Corporate Presentation - FY2021 Results  26/08/2021 10:45AM
CLINUVEL Delivers Record Revenues and Profit  26/08/2021 10:21AM
Appendix 4E and Preliminary Financial Report  26/08/2021 10:12AM
Afamelanotide well tolerated by first stroke patients  10/08/2021 9:08AM
Quarterly Activities/Appendix 4C Cash Flow Report  29/07/2021 9:21AM
Change of Director's Interest Notice  05/07/2021 10:15AM

Similar Companies

Related Articles

Load More

About Company

CLINUVEL PHARMACEUTICALS LIMITED (ASX: CUV) is a global biopharmaceutical that is into development of SCENESSE (its proprietary first-in-class drug, as a photoprotective) to manage a range of UV and light related skin disorders and other products for treating genetic disorders.

Corporate Information

company address Level 11, 535 Bourke Street, MELBOURNE, VIC, AUSTRALIA, 3000

company phone61 3 9660 4900

company websitehttp://www.clinuvel.com

Dividends

Year-end Date Franking DPS (AUD) Dividend Yield
30/06/2021 0% 0.025 0.08%
30/06/2020 0% 0.025 0.10%
30/06/2019 0% 0.025 0.07%
30/06/2018 0% 0.020 0.18%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-10-07 2022
Report (Prelim) 2022-08-26 2022
Report (Prelim) 2022-08-25 2022
Report (Interim) 2022-02-23 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue 47.976 M 32.565 M 31.048 M 25.486 M 16.72 M
Other Revenue 132,813 781,319 886,037 485,838 185,168
Total Revenue 48.108 M 33.347 M 31.934 M 25.972 M 16.905 M
Interest Income 342,203 562,928 564,657 264,452 264,394
Interest Expenses -1.618 M -25,886 -21,114 0 0
Expenses -20.258 M -20.32 M -14.148 M -13.249 M -10.002 M
EBITDA 27.85 M 13.027 M 17.785 M 12.722 M 6.903 M
Depreciation and Amortization -861,432 -427,628 -214,164 -44,543 -53,138
Depreciation -861,432 -427,628 -214,164 -44,543 -53,138
Amortisation 0 0 0 0 0
EBIT 26.989 M 12.599 M 17.571 M 12.678 M 6.85 M
Pre Tax Profit 25.713 M 13.136 M 18.115 M 12.942 M 7.114 M
Tax Expense -984,397 3.51 M 19,333 281,779 0
Net Profit After Tax 24.728 M 16.647 M 18.134 M 13.224 M 7.114 M
Minority Interest 0 0 0 0 66,541
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 0 0 0
Reported Net Profit After Abnormal Items 24.728 M 16.647 M 18.134 M 13.224 M 7.181 M
Ending Shares 49.41 M 49.41 M 48.961 M 47.824 M 47.735 M
Weighted Average Shares 51.091 M 50.445 M 49.547 M 49.529 M 50.216 M
EPS After Abnormal Items (cents) 48.4 33 36.6 26.7 14.3
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 102.848 M 75.156 M 61.153 M 42.269 M 28.47 M
Total Non Current Assets 5.719 M 6.386 M 1.193 M 635,548 137,341
Total Assets 108.568 M 81.542 M 62.345 M 42.905 M 28.607 M
Total Current Liabilities 8.707 M 6.66 M 4.96 M 3.471 M 3.148 M
Total Non Current Liabilities 1.123 M 1.213 M 205,477 17,808 15,337
Total Liabilities 9.83 M 7.873 M 5.166 M 3.489 M 3.163 M
Net Assets 98.737 M 73.669 M 57.18 M 39.416 M 25.444 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash 19.262 M 14.188 M 18.456 M 11.693 M 9.917 M
Net Invested Cash -854,325 -888,826 -257,616 -75,123 -67,479
Net Financing Cash Flows -1.48 M -1.486 M -1.031 M 0 85,082
Beginning Cash 66.747 M 54.269 M 36.198 M 23.752 M 13.845 M
End Cash Position 82.691 M 66.747 M 54.269 M 36.198 M 23.752 M
Exchange Rate Adjustments -983,324 664,084 902,482 827,929 -26,930
Other Cash Adjustments 0 0 0 0 0
Ending Cash 82.691 M 66.747 M 54.269 M 36.198 M 23.752 M

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK